Real World Experience and Randomized Clinical Trials

September 6-8, 2017

Here is the web  link for accessing Dr Robert Califf’s presentation on Friday September 8.

We have obtained permission of some speakers to share the slides and they can be found here.

A survey will soon be available about the content and format of the conference this year and the future conferences.

For  details about the special issue for Journal of Biopharmaceutical Statistics, please contact Dr Jean Pan ( and Dr Danyu Lin (

Prizes for best posters were awarded for: “A Modified Promising Zone Sample Size Re-estimation Design with Fixed Critical Value” by Xiaoyu Cai, Yi Tsong, Meiyu Shen of FDA and “A new approach for detecting safety signals in clinical trials” by Xianming Tan  from University of North Carolina at Chapel Hill.

A copy of the program book of the symposium can be downloaded from here.

The 5th Duke Annual Statistics Symposium (DISS) is organized by the Department of Biostatistics and Bioinformatics, Duke University School of Medicine, and co-sponsored by Amgen, Boehringer-Ingelheim, ICSA, Janssen, NC-ASA Chapter, PAREXEL, PPD, QuintilesIMS and SAS. It was established 5 years ago to discuss challenging issues and recent advances related to the clinical development of drugs, biologics and devices and to promote research and collaboration among statisticians from industry, academia, and regulatory agencies.

The theme for this year will be “Real World Experience and Randomized Clinical Trials.” DISS 2017 will be held on September 6-8, 2017 at the Durham Hilton in Durham, NC. The first day will be devoted to six short courses. The 2nd day will begin with opening remarks and keynote speech by Dr. Warren Kibbe,  faculty in the Duke Department of Biostatistics and Bioinformatics and Chief Data Officer for the Duke Cancer Institute.  He is the former Acting Deputy Director of the National Cancer Institute (NCI) and Director of the NCI’s Center for Biomedical Informatics and Information Technology.  The remainder of the 2nd day consists of 17 parallel scientific sessions.  On the final day, Dr. Robert Califf, with leadership roles in Duke University School of Medicine and Verily Life Sciences and the former FDA commissioner, will present a feature lecture and we will continue with the parallel scientific sessions. A poster session will also be held.